Anti-Elotuzumab Antibodies
-
Bioanalytical Antibodies
-
Antibodies for Bioanalysis and Drug Monitoring
-
Our Anti-Biotherapeutic Antibodies
- Anti-Abatacept Antibodies
- Anti-Adalimumab Antibodies
- Anti-Aflibercept Antibodies
- Anti-Alemtuzumab Antibodies
- Anti-Atezolizumab Antibodies
- Anti-Avelumab Antibodies
- Anti-Belatacept Antibodies
- Anti-Belimumab Antibodies
- Anti-Benralizumab Antibodies
- Anti-Bevacizumab Antibodies
- Anti-Brentuximab Antibodies
- Anti-Burosumab Antibodies
- Anti-Canakinumab Antibodies
- Anti-Cemiplimab Antibodies
- Anti-Certolizumab Antibodies
- Anti-Cetuximab Antibodies
- Anti-Daratumumab Antibodies
- Anti-Denosumab Antibodies
- Anti-Dulaglutide Antibodies
- Anti-Dupilumab Antibodies
- Anti-Durvalumab Antibodies
- Anti-Eculizumab Antibodies
- Anti-Elotuzumab Antibodies
- Anti-Emicizumab Antibodies
- Anti-Etanercept Antibodies
- Anti-Evolocumab Antibodies
- Anti-Golimumab Antibodies
- Anti-Guselkumab Antibodies
- Anti-Ixekizumab Antibodies
- Anti-Infliximab Antibodies
- Anti-Ipilimumab Antibodies
- Anti-Natalizumab Antibodies
- Anti-Nivolumab Antibodies
- Anti-Nirsevimab Antibodies
- Anti-Obinutuzumab Antibodies
- Anti-Ocrelizumab Antibodies
- Anti-Omalizumab Antibodies
- Anti-Palivizumab Antibodies
- Anti-Panitumumab Antibodies
- Anti-Pembrolizumab Antibodies
- Anti-Pertuzumab Antibodies
- Anti-Ramucirumab Antibodies
- Anti-Ranibizumab Antibodies
- Anti-Risankizumab Antibodies
- Anti-Rituximab Antibodies
- Anti-Romosozumab Antibodies
- Anti-Sarilumab Antibodies
- Anti-Secukinumab Antibodies
- Anti-Tocilizumab Antibodies
- Anti-Trastuzumab Antibodies
- Anti-Tremelimumab Antibodies
- Anti-Ustekinumab Antibodies
- Anti-Vedolizumab Antibodies
- Anti-Isatuximab Antibodies
-
Our Anti-Biotherapeutic Antibodies
-
Antibodies for Bioanalysis and Drug Monitoring
s
s
s
Antibodies for bioanalysis and drug monitoring of elotuzumab and biosimilars
Develop highly selective and sensitive PK and ADA assays for the humanized antibody drug elotuzumab (Empliciti®) using our range of ready-made anti-idiotypic antibodies.
- Inhibitory antibodies specific to elotuzumab
- Fully human surrogate positive control or calibrator
- Sequence defined, well characterized reagents with secure supply
- Recombinant production, stringent quality control for batch-to-batch consistency
- Non-animal-derived antibodies, reducing the use of animals in science
Table 1. Antibodies Specific to Elotuzumab.
Specificity |
Catalog Number |
Clone |
Format |
Affinity* KD, nM |
Assay Recommendation |
Product Details |
|---|---|---|---|---|---|---|
|
Elotuzumab Inhibitory Type 1 |
HCA438 |
AbD60180ia |
Human IgG1 |
3.7 |
ADA assay |
|
|
HCA439 |
AbD60183ia |
Human IgG1 |
0.9 |
ADA assay |
||
|
HCA440 |
AbD60184ia |
Human IgG1 |
0.7 |
ADA assay |
||
|
TZA0115 |
AbD60179ad |
Fab-F-Spy2-H1 |
0.9 |
PK bridging ELISA (capture) |
||
|
TZA0116 |
AbD60184ad |
Fab-F-Spy2-H1 |
0.7 |
PK bridging ELISA (detection) |
||
|
TZA0116P |
AbD60184pap |
Fab2-FH-X22-HRP2 |
0.7 |
PK bridging ELISA (detection) |
* Affinity measured in the monovalent Fab format.
1 Fab-F-Spy2-H = Monovalent Fab antibody with (F) DYKDDDDK, (Spy2) SpyTag version 2, and (H) His-6-tags.
2 Fab2-FH-X22-HRP = Bivalent Fab antibody with (F) DYKDDDDK, (H) His-6-tags, and Fab-SpyTag coupled to HRP-conjugated BiCatcher.
Anti-Elotuzumab Inhibitory Antibodies (Type 1)
Type 1 anti-elotuzumab antibodies inhibit the binding of the drug elotuzumab to its target, SLAM7 (signaling lymphocytic activation molecule family member 7 protein). They are ideal for development of a pharmacokinetic (PK) bridging ELISA to measure free drug. In fully human IgG1 format, they are suitable as a surrogate positive control or calibrator for an anti-drug antibody (ADA) assay.
TrailBlazer Antibodies
TrailBlazer™ Antibodies, clones TZA0115 AbD60179ad (Type 1) and TZA0116 AbD60184ad (Type 1) have a SpyTag2 incorporated at the C-terminus of the antibody heavy chain. In a fast reaction that simply requires mixing at room temperature, these antibodies can form a covalent isopeptide bond to a SpyCatcher reagent, enabling site-directed conjugation or fast conversion to a bivalent Fab or a full-length Ig-like format within an hour.
ELISA Protocols to Get You Started
PK Bridging ELISA
Fig. 1. Elotuzumab PK bridging ELISA using antibodies TZA0115 (capture) and TZA0116P (detection).
Schematic image of PK bridging ELISA detecting free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Fab format (purple), labeled with HRP.
ADA Bridging ELISA
Fig. 2. Elotuzumab ADA bridging ELISA using antibodies HCA438, HCA439, and HCA440.
Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).
Resources
Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.